255 related articles for article (PubMed ID: 15541261)
1. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
[TBL] [Abstract][Full Text] [Related]
2. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
5. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
Sargento L; Brito D; Matias JS; Madeira H
Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
10. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
11. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of acute decompensated heart failure with levosimendan].
Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
[TBL] [Abstract][Full Text] [Related]
15. [Additive effects of milrinone and dobutamine in severe heart failure].
Meissner A; Herrmann G; Gerdesmeyer L; Simon R
Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
[TBL] [Abstract][Full Text] [Related]
19. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
Segreti JA; Marsh KC; Polakowski JS; Fryer RM
J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Mebazaa A; Erhardt L
Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
